Lupus & antiphospholipid syndrome

Prognostic value of the modified National Institute of health activity and chronicity scoring system in predicting end-stage kidney disease in Latin American lupus nephritis patients

LupusPublished Retrospective cohort study

Authors' conclusion

In Latin American LN patients, the mNIH activity and chronicity indices are associated with an increased risk of ESKD. Among the components of these indices, shorter time to ESKD was mainly driven by fibrinoid necrosis and fibrous crescents.

Study context

Population
Latin American patients with biopsy-proven lupus nephritis (LN)biopsy-proven LN
Participants
412 patients
Exposure
Modified National Institute of Health (mNIH) activity and chronicity indices as predictors of end-stage kidney disease (ESKD)
  • ESKDn = 84
Outcome
Progression to ESKD (estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m² for ≥3 months, dialysis for >3 months, or kidney transplant)
Methodological detailsunivariable and multivariable Cox proportional hazards regression
  • Univariable and multivariable Cox proportional hazards regression

Main finding

As reported in the abstract

Association of mNIH indices with ESKD (multivariable Cox, adjusted for age, sex, ethnicity, eGFR)
Hazard ratio (95% CI)
mNIH activity index
1.17(1.05–1.29)
mNIH chronicity index
1.21(1.05–1.40)

Observational data: associations, not effects.

Further findings

Index components and time to ESKD

HR (95% CI)
Fibrinoid necrosis4.09 (1.54–10.86)
Fibrous crescents2.36 (1.06–5.27)
OutcomeESKDNo ESKDP value
mNIH activity index7 (range 5–10)4 (range 1–7)P < 0.001
mNIH chronicity index3 (range 1–5)0 (range 0–2)P < 0.001

Original publication

Prognostic value of the modified National Institute of health activity and chronicity scoring system in predicting end-stage kidney disease in Latin American lupus nephritis patients. Lupus. Published 4 March 2025. doi:10.1177/09612033251325315

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.